Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ovarian cancer
ovarian cancer
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Fierce Biotech
Tue, 08/9/22 - 06:29 am
Clovis Oncology
Rubraca
ovarian cancer
funding
Gene therapy for ovarian cancer fails PhIII study — sinking VBL Therapeutics' shares
Endpoints
Wed, 07/20/22 - 09:33 am
VBL Therapeutics
gene therapy
ovarian cancer
VB-111
ofra-vec
ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance
Fierce Pharma
Mon, 06/6/22 - 09:57 am
ASCO 2022
Clovis
Rubraca
ovarian cancer
FDA
Roche pays Repare $125M to join Big Pharma peers in cancer race
Fierce Biotech
Thu, 06/2/22 - 10:36 am
Roche
cancer
ovarian cancer
Repare Therapeutics
ASCO Preview: Immutep, InxMed and Faron Release New Clinical Findings
BioSpace
Tue, 05/31/22 - 10:49 am
ASCO 2022
IMMUTEP
non-small cell lung cancer
InxMed
ovarian cancer
Faron Pharmaceuticals
solid tumors
Researchers Use Emerging Ovarian Cancer Biomarker to Develop New Blood Test for Ovarian Cancer
Xtalks
Tue, 05/10/22 - 10:41 am
diagnostics
ovarian cancer
biomarkers
FDA
Clovis quietly unveils crippling FDA delay as its troubles deepen
Fierce Pharma
Fri, 05/6/22 - 11:05 am
Clovis Oncology
FDA
Rubraca
ovarian cancer
AACR22: As post-Covid development takes shape, BioNTech reports first human data for CAR-T/cancer vaccine combo
Endpoints
Sun, 04/10/22 - 07:49 pm
AACR
BioNTech
clinical trials
CAR-T
MRNA
testicular cancer
ovarian cancer
Clovis equity investors overlook two elephants
EP Vantage
Fri, 04/1/22 - 10:27 am
Clovis Oncology
Rubraca
ovarian cancer
Corcept, Clovis Score Wins in Advanced Ovarian Cancer
BioSpace
Thu, 03/31/22 - 10:32 am
Clovis Oncology
Corcept Therapeutics
ovarian cancer
clinical trials
ImmunoGen Ovarian Cancer Drug Reaches BLA Milestone
BioSpace
Tue, 03/29/22 - 11:37 pm
Immunogen
ovarian cancer
FDA
mirvetuximab soravtansine
Verastem takes on debt to get RAS tumor program to finish line
Fierce Biotech
Mon, 03/28/22 - 10:10 am
Verastem
ovarian cancer
non-small cell lung cancer
funding
Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Fierce Biotech
Mon, 03/21/22 - 10:17 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
clinical trials
antibody-drug conjugate
Sutro’s folate challenge to Immunogen hits a problem
EP Vantage
Fri, 01/7/22 - 10:29 am
Sutro
STRO-002
ovarian cancer
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial
Fierce Biotech
Tue, 11/30/21 - 10:29 am
Immunogen
mirvetuximab soravtansine
ovarian cancer
FDA
antibody-drug conjugate
VCs back Leucid to trial CAR-T twist in ovarian cancer patients
Fierce Biotech
Thu, 10/21/21 - 10:40 am
Leucid Bio
CAR-T
ovarian cancer
clinical trials
venture capital
Two More Cancer Drug Candidates Hit the Fast Track
BioSpace
Mon, 08/16/21 - 12:16 pm
ovarian cancer
breast cancer
fast track status
IN10018
InxMed
Carrick Therapeutics
samuraciclib
Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion
Endpoints
Wed, 05/5/21 - 10:42 am
Clovis Oncology
earnings
Lucitanib
Opdivo
Bristol Myers Squibb
ovarian cancer
Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval
BioSpace
Tue, 04/20/21 - 10:56 am
Anixa Biosciences
FDA
CAR-T
ovarian cancer
Mersana starts to lose its shine
EP Vantage
Wed, 01/6/21 - 10:38 am
Mersana
ovarian cancer
XMT-1536
antibody-drug conjugate
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »